| INTRODUC TI ON
Recurrence of hepatitis C virus infection after liver transplantation is universal in patients who have detectable HCV-RNA at the time of surgery. 1 The natural history of recurrence in HCV-infected patients is accelerated compared with immunocompetent patients, and 20% to 30% develop cirrhosis within 5 years of transplantation.
2 Post-LT patient and graft survival are significantly lower in HCV/HIV-coinfected than in HCV-monoinfected recipients, owing to more rapid progression of fibrosis and a higher incidence of severe forms of recurrence of HCV infection (including fibrosing cholestatic hepatitis). 3 In the interferon (IFN) era, viral eradication was associated with improved clinical and histological outcomes (reduction in portal pressure, regression of fibrosis, and resolution of clinical decompensations in cirrhotic patients). [4] [5] [6] However, IFN based therapies were associated with a low rate of sustained virological response (SVR) and a high rate of treatment discontinuation due to adverse events. 2 This was especially true for HCV/ HIV-coinfected LT recipients, in whom the SVR rate was 14% to 21%, which was significantly lower than in HCV-monoinfected recipients. 7, 8 Fortunately, the emergence of direct-acting antivirals (DAAs) has completely changed treatment of HCV infection. Clinical trials and real-life cohort studies based on HCV-monoinfected LT recipients have shown excellent results in terms of efficacy and safety, especially in patients with mild fibrosis and compensated cirrhosis (SVR rate ≈ 90%). [9] [10] [11] [12] Nevertheless, data on the efficacy and safety of DAAs in HCV/HIV-coinfected LT recipients are limited to case series and individual case reports. The largest series was published by Campos-Varela et al, 13 who evaluated the outcome of a sofosbuvir (SOF)-based compassionate use program in HCV/HIV-coinfected LT recipients. The authors found that 20 patients with early recurrence of severe HCV infection or cirrhosis received SOF-based antiviral therapy. SVR was 89% and was followed by improved liver function results (bilirubin and albumin levels) and the resolution of clinical decompensations in most of the decompensated patients. Eight patients experienced serious adverse events, although none were related to therapy. In a recent series of seven HCV/HIV-coinfected LT recipients with severe HCV recurrence taking different combinations of DAAs, all seven patients achieved SVR, and only four experienced mild adverse events. 14 In another study, one patient treated with SOF and daclatasvir (DCV) presented severe bradycardia. 13, 15 In two recently published studies 24 16 and 29, 17 HIV-infected LT recipients achieved a 90% and 96% SVR rates with SOF-based DAAs regimens, respectively. However, they did not include a control group.
Despite these excellent results for effectiveness and tolerability in HCV/HIV-coinfected LT recipients, which appear to be similar Direct-acting antivirals have proved to be highly efficacious and safe in monoinfected liver transplant (LT) recipients who experience recurrence of hepatitis C virus (HCV) infection. However, there is a lack of data on effectiveness and tolerability of these regimens in HCV/HIV-coinfected patients who experience recurrence of HCV infection after LT. In this prospective, multicenter cohort study, the outcomes of 47 HCV/HIV-coinfected LT patients who received DAA therapy (with or without ribavirin [RBV] ) were compared with those of a matched cohort of 148 HCV-monoinfected LT recipients who received similar treatment. Baseline characteristics were similar in both groups. HCV/HIV-coinfected patients had a median (IQR) CD4 T-cell count of 366 (256-467) cells/µL. HIV-RNA was <50 copies/mL in 96% of patients. The DAA regimens administered were SOF + LDV ± RBV (34%), SOF + SMV ± RBV (31%), SOF + DCV ± RBV (27%), SMV + DCV ± RBV (5%), and 3D (3%), with no differences between the groups. Treatment was well tolerated in both groups. Rates of SVR (negative serum HCV-RNA at 12 weeks after the end of treatment) were high and similar for coinfected and monoinfected patients (95% and 94%, respectively; P = .239). Albeit not significant, a trend toward lower SVR rates among patients with advanced fibrosis (P = .093) and genotype 4 (P = .088) was observed. In conclusion, interferon-free regimens with DAAs for post-LT recurrence of HCV infection in HIV-infected individuals were highly effective and well tolerated, with results comparable to those of HCV-monoinfected patients.
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| ME THODS

| Study design
We performed a multicenter nationwide cohort study of 250
consecutive HCV/HIV-coinfected patients who underwent LT be- Figure 1 ). The institutional review boards of all the participating sites approved the study. All patients signed the informed consent form.
As shown in Figure 1 , 49 HCV/HIV-coinfected patients and 165
HCV-monoinfected patients received INF-free antiviral therapy for recurrence of hepatitis C following LT. After exclusion of two coinfected patients and 17 monoinfected patients who were still on treatment at the time of the analysis, the final study population comprised 47 coinfected and 148 monoinfected patients.
Pre, peri, and posttransplant variables for coinfected patients were collected at each site using a standardized case report form as previously described. Months between LT and first anti-HCV treatment 43.8 [16.5;78.7] 41. 3 [16.7;68.4] 45.0 [16.5;79.9] .144
| Antiviral therapy with INF-free regimens
Months between LT and DAA-based anti-HCV treatment Table S1 ).
Rapid virological response and end of treatment response were defined as a negative plasma HCV RNA viral load at 4 weeks and at the end of therapy, respectively. SVR was defined as a persistently negative plasma HCV-RNA viral load at 12 weeks after the end of treatment. HCV-RNA breakthroughs were defined as one or more undetectable HCV-RNA values during treatment, but not two consecutive undetectable HCV-RNA values at the end of treatment.
Relapse was defined as a positive plasma HCV-RNA viral load in a patient meeting the criteria for end of treatment response. Biochemical response was defined as the normalization of aminotransferase levels at the end of treatment.
| Statistical analysis
Analyses were primarily conducted by a modified intention-to-treat analysis, which only excluded those patients who had a virological response but had not finished treatment at the time of the analysis.
Categorical variables were expressed as a frequency (percentage).
Continuous variables were expressed as mean (standard deviation)
or median (interquartile range). As HIV+ individuals were originally matched in a proportion 1:3 with HCV-monoinfected individuals, conditional logistic regression was used to compare variables between HCV/HIV-coinfected and HCV-monoinfected patients. 19 Confidence intervals for categorical variables were calculated with the exact binomial. To compare values between the start and end of treatment, patients whose treatment failed were excluded and a paired t test was used. A P < .05 was considered to indicate statistical significance. Statistical analyses were performed with R, version 3.3.2 (2016-10-31 ).
| RE SULTS
| Characteristics of patients
The study population comprised 195 LT recipients who received antiviral therapy with an IFN-free regimen. Of these, 47 were HCV/HIV-coinfected and 148 were HCV-monoinfected. The baseline characteristics of these patients are shown in Table 1 . Briefly, most of the patients were male (n = 156, 80%) with a mean age of All but one patient (98%) was on antiretroviral therapy (cART). Table   S2 summarizes the cART received during treatment with DAAs. Only five patients (11.1%) required a modification in cART before starting treatment with DAAs. All but one was switched to ART based on a nonboosted INSTI (raltegravir, two cases; dolutegravir, two cases).
The other case was a patient with a multidrug-resistant virus who was receiving a PI-based regimen plus RAL and TDF/FTC before being switched to TDF/FTC/rilpivirine plus dolutegravir based on a historic genotyping analysis. The DAA dose did not have to be adjusted in any cases.
| Efficacy of antiviral therapy
The antiviral regimen administered is shown in Table 1 . Combinations including SMV (SMV + SOF and SMV + DCV with or without RBV)
were the most commonly administered to HIV negative recipients (82% of patients receiving SMV were HIV negative), but the difference between HIV positive and HIV negative recipients was not statistically significant (P = .121). Most of the patients received RBV (n = 136, 67.9%) with a median dose of 800 mg/day with no difference between HIV positive and HIV negative recipients. The only significant difference between patients taking RBV and those not was the type of antiviral regimen. As shown in Table S3 , the HIV infected individuals receiving suboptimal combinations such as SMV + SOF or SMV + DCV were those on RBV (P = .004). The SVR rate was 94%
in HCV/HIV-coinfected patients and 95% in HCV-monoinfected 
TA B L E 1 (Continued)
patients (P = .239) ( Table 2) . Interestingly, the mITT RVR (week 4 of antiviral therapy) was significantly better in HCV/HIV-coinfected patients than in HCV-monoinfected recipients (100% vs. 75.8%; P = .004). Treatment failures (n = 10) were due to relapse in six cases, viral breakthrough in three, and death during therapy in one case (Table 3 ). The three breakthrough episodes were observed exclusively in patients treated with SMV + DCV. Six patients (cases 1-4, 8, and 9 in Table 3 ) received a second IFN-free regimen and all achieved SVR. There were no significant differences in the baseline characteristics among patients with or without SVR (Table S4 ). There was a trend towards a high number of patients with F4 among those who failed antiviral therapy as compared to patients who achieved SVR (70% vs. 38.9%; P = .093). Interestingly, when specifically analyzing HIV-positive recipients, the SVR rate was significantly associated to the type of DAA regimen administered to the patient (P = .004), and especially for patients receiving SMV as part of a DAA regimen (P = .018). See Table S5 for details.
With regard to specific HCV genotypes, it is interesting to note that in genotype 4-infected patients, SVR tended to be lower (albeit not significantly) in HCV/HIV-coinfected patients than in HCV-monoinfected (77.8% vs. 90.9%; P = .566). However, the two virological failures observed in coinfected patients received antiviral therapy with SMV + DCV + RBV, which is currently considered a suboptimal combination.
The INF-free regimens were very well tolerated, and none of the HIV-infected patients needed to stop them because of adverse events. Only one HCV-monoinfected cirrhotic patient died during therapy (liver decompensation). Three out of 47 (6.38%) coinfected patients and five out of 148 (3.38%) monoinfected patients required erythropoietin or darbepoetin because of mild anemia, with no significant differences between the two groups (P = .40).
Adjustments in immunosuppressive (IS) medication were more frequent in HIV positive recipients (51.1% vs. 37.2% in HIV-negative patients) but the difference was not statistically significant (P = .11).
When a detailed analysis of IS modification was performed, we observed that HIV-positive recipients more frequently underwent a decrease in calcineurin inhibitor (CNI) dose (P = .006) and the addition of another IS drug (P = .013), mainly mycophenolate (MMF).
These data are shown in Table S6 . Despite the need for IS adjustment, none of the patients developed T-cell mediated rejection.
| Impact of therapy on liver tests
As expected, there was a significant improvement in transaminase levels, γ-glutamyl-transpeptidase levels, and alkaline phosphatase in HCV/HIV-coinfected patients at the end of treatment compared with baseline. However, viral eradication did not have an impact on the results of liver function tests (bilirubin, albumin, INR, and MELD score). These data are reported in Table 4 . Figure 2 shows the delta MELD at the time of SVR (as compared to baseline) in coinfected patients with SVR.
| Impact of therapy on hematological, renal, and HIV virological test results
As expected with the concomitant use of RBV in some patients, a significant decrease in hemoglobin levels was observed in the (Table 5 ) nor in renal function test (creatinine, estimated glomerular filtration rate, Table 4 ). DAAs did not affect plasma HIV RNA viral load, which was below detection levels at the end of treatment in most cases (Table 5 ).
| D ISCUSS I ON
Despite growing data on the safety and efficacy of antiviral therapy in HIV-negative HCV-infected LT recipients, [9] [10] [11] [12] 20 data on HCV/ HIV-coinfected LT recipients remain scarce and are based only on small case series. [13] [14] [15] [16] [17] We report the results of the first nationwide, multicenter, prospective case-control study on the effectiveness and tolerability of antiviral therapy with DAAs in HCV/HIV-coinfected patients with recurrence of hepatitis C after LT and a matched cohort of monoinfected recipients. The SVR rate in HCV/HIV-coinfected recipients was high and similar to that of HCV-monoinfected LT patients (94% vs. 95%, P = .239). Antiviral therapy was well tolerated, and only one HIV-negative patient died (complications of cirrhosis).
In the IFN era, the SVR rate in coinfected LT recipients with recurrence of hepatitis C was significantly lower than in HCV-monoinfected patients. A prospective cohort study by our group (FIPSE Investigators) 7 showed that the SVR rate was significantly lower in coinfected than in monoinfected LT recipients (21% vs. 36%; P = .013).
Treatment discontinuation was also significantly more frequent in coinfected recipients (56% vs. 39%; P = .016). The addition of a firstgeneration protease inhibitor (TVR or BOC) to the antiviral therapy regimen (triple therapy) was a major step forward in the treatment of hepatitis C, with a substantial increase in SVR rates. 3 However, in LT recipients, the use of this therapy was hampered by two relevant issues:
(1) the significant number of adverse events observed in this group;
TA B L E 3 Characteristics of patients whose first IFN-free treatment regimen failed 8.92 [7.34;11.8] 9.73 [8.06;11.2] .446
ALT, alanine aminotransferase; AST, aspartate aminotransferase; AP, alkaline phosphatase; eGFR, estimated glomerular filtration rate (by CKDEpi); INR, international normalized ratio; MELD, Model for end-stage liver disease.
and (2) In HCV-monoinfected LT recipients, the SVR rate ranged between 71% and 97% depending on the antiviral regimen, HCV genotype, and fibrosis stage. [9] [10] [11] [12] 20, 24 Tolerance to antiviral therapy was excellent with all combinations, although drug-drug interactions are likely with some DAAs (3D includes ritonavir and markedly increases calcineurin inhibitor levels, 24 and SMV should not be used with cyclospo- reported to achieve 90% and 96% of SVR, respectively. In most of these studies there was no control group.
To the authors' knowledge, this is the first nationwide cohort study to compare the effectiveness and tolerability of DAAs in coinfected and monoinfected LT recipients. As expected, the intention-to-treat SVR rate was very similar between the two groups: 94% vs. 95%. The main difference between coinfected and monoinfected recipients was observed in genotype 4-infected patients, in whom SVR rates were 74% and 91%, respectively. However, this difference did not reach statistical significance (P = .566), probably owing to the small number of patients in this subgroup. Overall, 10 patients failed to achieve SVR (see Table 3 for details). Interestingly, four out of the 10 patients whose treatment failed received SMV + DCV ± RBV, which is currently considered a suboptimal combination. Besides, 70% of patients who failed antiviral therapy had F4 fibrosis. This was higher (although not statistically significant) than the proportion of patients with F4 among LT recipients who achieved SVR (39%; P = .093). The addition of RBV to the antiviral regimen did not impact the chances of achieving SVR. This could be due to the fact that HIV-positive recipients who did not receive RBV were predominantly treated for 24 weeks. However, it is possible that liver transplant recipients receiving a potent antiviral combination (SOF plus an NS5A inhibitor) do not require RBV despite receiving a 12-week treatment duration, as shown by Houssel-Debry et al.
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Among the HIV-infected LT recipients, only four needed to switch their cART to two nucleot(s)ide reverse transcriptase inhibitors plus a nonboosted INSTI. None of the INF-free regimens used in these patients impacted on the CD4+ T-cell counts or the plasma HIV-RNA load, which was maintained below detection levels in most cases.
Immunosuppression adjustments were more frequently observed in HIV-positive patients mainly due to decrements in CNI doses and the addition of another drug (MMF). This was probably related with potential interaction with antiviral and antiretroviral regimens.
Despite the need for IS adjustment, no patients developed rejection, indicating that under close supervision by a multidisciplinary team, antiviral therapy with DAAs is safe in HIV-positive recipients.
As expected after viral eradication, we observed an improvement in liver enzyme values. However, this improvement was not noted in tests to assess liver function, such as bilirubin, albumin, INR, and MELD score. This discrepancy could have been due to the short period over which these parameters changed, namely, from the TA B L E 5 Changes in lymphocyte, CD4 and CD4/CD8 T-cell counts, and plasma HIV RNA viral load from initiation to end of treatment in the 44 coinfected patients with SVR F I G U R E 2 Delta MELD score from baseline to the time of SVR of the 44 HCV/HIV-coinfected patients with SVR. Median baseline and SVR MELD score were ), P = .446
initiation to the time of achieving SVR. It is probable that a longer follow-up will reveal an improvement in liver function.
Our study has several limitations. First, the number of patients In conclusion, treatment of post-LT recurrence of hepatitis C in HIV-infected individuals IFN-free regimens (ie, DAA-based regimens) was highly effective and well tolerated. The results were comparable to those observed for HCV-monoinfected patients.
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